AA
ALXN

ALPS Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

ALPS Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,087
Closed -$1.12M – 1062
2021
Q2 		$1.12M Sell
6,087
-139
-2% -$23.9K 0.01% 392
2021
Q1 		$952K Sell
6,226
-1,029
-14% -$159K 0.01% 402
2020
Q4 		$1.13M Sell
7,255
-690
-9% -$88.7K 0.01% 376
2020
Q3 		$909K Buy
+7,945
New +$857K 0.01% 363
2018
Q1 		– Sell
-3,265
Closed -$390K – 1021
2017
Q4 		$390K Hold
3,265
– – ﹤0.01% 686
2017
Q3 		$458K Sell
3,265
-1,607
-33% -$218K ﹤0.01% 654
2017
Q2 		$593K Buy
4,872
+945
+24% +$110K ﹤0.01% 365
2017
Q1 		$476K Buy
+3,927
New +$506K ﹤0.01% 546
2015
Q3 		– Sell
-2,868
Closed -$518K – 796
2015
Q2 		$518K Buy
2,868
+44
+2% +$7.59K ﹤0.01% 467
2015
Q1 		$489K Sell
2,824
-444
-14% -$80.4K ﹤0.01% 600
2014
Q4 		$605K Sell
3,268
-432
-12% -$80K ﹤0.01% 260
2014
Q3 		$614K Buy
+3,700
New +$608K ﹤0.01% 237
2014
Q1 		– Sell
-4,176
Closed -$663K – 695
2013
Q4 		$663K Buy
4,176
+2,032
+95% +$244K 0.01% 169
2013
Q3 		$249K Buy
+2,144
New +$235K ﹤0.01% 457

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

ALPS Advisors's ALXN Position: Q3 2021 in Review

ALPS Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 6,087 shares — an estimated $1.12M sold.

ALPS Advisors first reported a position in ALXN in Q3 2013 and held it in 14 quarters. The position peaked at $1.13M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • ALPS Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • ALPS Advisors sold 6,087 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.12M.
  • ALPS Advisors first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 14 quarters.
  • ALPS Advisors's Alexion Pharmaceuticals position peaked at $1.13M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on ALPS Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.